Rojas A, Lindner C, Schneider I, González I, Morales MA. Contributions of the receptor for advanced glycation end products axis activation in gastric cancer. World J Gastroenterol 2023; 29(6): 997-1010 [PMID: 36844144 DOI: 10.3748/wjg.v29.i6.997]
Corresponding Author of This Article
Armando Rojas, PhD, Full Professor, Senior Researcher, Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, 3605 San Miguel Ave., Talca 34600000, Chile. arojasr@ucm.cl
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Armando Rojas, Ileana González, Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, Talca 34600000, Chile
Cristian Lindner, Iván Schneider, Medicine Faculty, Catholic University of Maule, Talca 34600000, Chile
Miguel Angel Morales, Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Santiago 8320000, Chile
Author contributions: All authors contributed to the original ideas and writing of this paper; Rojas A designed the report and wrote the paper; Lindner C created the artwork and performed data acquisition, drafting and revision of the manuscript; Schneider I, González I and Morales MA contributed to the data acquisition, drafting and revision of the manuscript.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Armando Rojas, PhD, Full Professor, Senior Researcher, Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, 3605 San Miguel Ave., Talca 34600000, Chile. arojasr@ucm.cl
Received: October 21, 2022 Peer-review started: October 21, 2022 First decision: November 14, 2022 Revised: November 26, 2022 Accepted: January 11, 2023 Article in press: January 11, 2023 Published online: February 14, 2023 Processing time: 111 Days and 13.5 Hours
Abstract
Compelling shreds of evidence derived from both clinical and experimental research have demonstrated the crucial contribution of receptor for advanced glycation end products (RAGE) axis activation in the development of neoplasms, including gastric cancer (GC). This new actor in tumor biology plays an important role in the onset of a crucial and long-lasting inflammatory milieu, not only by supporting phenotypic changes favoring growth and dissemination of tumor cells, but also by functioning as a pattern-recognition receptor in the inflammatory response to Helicobacter pylori infection. In the present review, we aim to highlight how the overexpression and activation of the RAGE axis contributes to the proliferation and survival of GC cells as and their acquisition of more invasive phenotypes that promote dissemination and metastasis. Finally, the contribution of some single nucleotide polymorphisms in the RAGE gene as susceptibility or poor prognosis factors is also discussed.
Core Tip: During the last two decades, new evidence supported by basic and clinical research has supported the role of the receptor for advanced glycation end products (RAGE) axis as a crucial actor in gastric carcinogenesis. We herein discuss how RAGE overexpression and RAGE activation-mediated signaling mechanisms are the main contributions of the RAGE axis to tumor development, migration, and metastasis in gastric cancer.
